Randomized trial · people
Tesamorelin: denser, larger trunk muscles at 26 weeks in HIV
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In people with HIV whose belly fat fell on tesamorelin, trunk muscles also became denser and somewhat larger over 26 weeks compared with placebo.
- Kind
- Randomized trial
- Studied in
- People
- Published
- 2019
- Journal
- J Frailty Aging
What they tested
The team wanted to know whether tesamorelin changes the quality (density) and size (area) of skeletal muscle in people with HIV and belly fat.
How the study was done
An exploratory secondary analysis of two earlier randomized, placebo-controlled trials at US and Canadian sites, comparing 193 tesamorelin responders with 148 placebo participants over 26 weeks. Responders were people whose deep belly fat (visceral fat) dropped by 8% or more, and trunk muscles were measured on CT scans at the low back.

What they found
After adjusting for starting values, tesamorelin was linked to larger gains than placebo in the density of four trunk muscle groups, by 1.56 to 4.86 Hounsfield units (a CT measure of density), all with p<0.005. Lean density also rose in the abdominal side-wall and rectus muscles, by 1.39 and 1.78 Hounsfield units. Total area grew in the rectus and psoas muscles, by 0.44 and 0.46 square centimeters, and lean muscle area grew in all four groups, by 0.64 to 1.08 square centimeters.
What it doesn’t show
This was an exploratory look back at older trials, and only tesamorelin users whose belly fat clearly dropped were included, so it doesn't show what happens in everyone who takes it. Most participants were white (83%) and male (87%), the study lasted 26 weeks, and it did not test effects on daily function or people without HIV.
The paper
Adrian et al. The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV. J Frailty Aging. 2019.
The compound
More studies on Tesamorelin
- Tesamorelin: visceral fat down 27.71 cm² in HIV lipodystrophyMeta-analysis · people · 2026
- Tesamorelin shifted liver gene activity in HIV-related fatty liverRandomized trial · people · 2020
- Tesamorelin: no change in glucose control in type 2 diabetesRandomized trial · people · 2017
- Tesamorelin cut visceral and liver fat over 6 months in HIV patientsRandomized trial · people · 2014
- Tesamorelin had little effect on simvastatin and ritonavir levelsRandomized trial · people · 2013
- Tesamorelin cut visceral fat 15.4% vs placebo in HIV at 26 weeksRandomized trial · people · 2010
- Every study on Tesamorelin
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.